BCL6公司
DNA甲基化
DNMT1型
弥漫性大B细胞淋巴瘤
淋巴瘤
甲基化
癌症研究
细胞
DNA
生物
分子生物学
病理
医学
基因表达
基因
B细胞
免疫学
遗传学
抗体
生发中心
作者
Junna Jiao,Zhuangwei Lv,Ping Zhang,Yang Wang,Meng Yuan,Xiaozhuo Yu,Woodvine otieno Odhiambo,Mingzhe Zheng,Hua Zhang,Yunfeng Ma,Yanhong Ji
出处
期刊:Neoplasia
[Elsevier]
日期:2020-02-12
卷期号:22 (3): 142-153
被引量:26
标识
DOI:10.1016/j.neo.2020.01.002
摘要
The BCL6 proto-oncogene encodes a transcriptional repressor, which is required for germinal centers (GCs) formation and lymphomagenesis. Previous studies have been reported that the constitutive expression of BCL6 leads to diffuse large B cell lymphoma (DLBCL) through activation-induced cytidine deaminase (AID) mediated chromosomal translocations and mutations. However, other DLBCLs (45%) without structural variants were characterized by abnormally high level of BCL6 expression through an unknown mechanism. Herein, we report that deficiency in AID or methyltransferase 1 (DNMT1) triggers high level of BCL6 expression. AID-DNMT1 complex binds to -0.4 kb -0 kb region of BCL6 promoter and contributes to generate BCL6 methylation which results in inhibition of BCL6 expression. The proteasome pathway inhibitor MG132 induces accumulation of AID and DNMT1, causes decreased BCL6 expression, and leads to cell apoptosis and tumor growth inhibition in DLBCL cell xenograft mice. These findings propose mechanistic insight into an alternative cofactor role of AID in assisting DNMT1 to maintain BCL6 methylation, thus suppress BCL6 transcription in DLBCL. This novel mechanism will provide a new drug selection in the therapeutic approach to DLBCL in the future.
科研通智能强力驱动
Strongly Powered by AbleSci AI